https://www.selleckchem.com/pr....oducts/bozitinib.htm
Clinically important deterioration (CID) is a multicomponent measure for assessing disease worsening in chronic obstructive pulmonary disease (COPD). This analysis investigated the prognostic value of a CID event on future clinical outcomes and the effect of single-inhaler triple dual therapy on reducing CID risk in patients in the IMPACT trial. IMPACT was a phase III, double-blind, 52-week, multicentre trial. Patients with symptomatic COPD and at least one moderate/severe exacerbation in the prior year were randomised 221 to fluticas
إعجاب
علق
شارك
